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Abstract
Quantitative 2D and 3D contrast-enhanced ultrasound (CEUS) was assessed to evaluate early 
transarterial chemoembolization (TACE) treatment response. Seventeen patients scheduled for 
TACE for the treatment of hepatocellular carcinoma participated in the study. 2D and 3D CEUS 
were performed for each patient at three time points: prior to TACE, 1–2 weeks post TACE, and 1 
month post TACE. Peak-intensities of the tumor and surrounding liver tissue were calculated from 
2D and 3D data before and after TACE and used to evaluate tumor treatment response. Residual 
tumor percentages were calculated from 2D and 3D CEUS acquired 1–2 weeks and 1 month post 
TACE and compared with results from MRI 1 month post TACE. Nine subjects had complete 
response while 8 had incomplete response. Peak-intensities of the tumor from 3D CEUS prior to 
TACE were similar between the complete and incomplete treatment groups (p=0.70), while 1–2 
weeks (p<0.01) and 1 month post treatment (p<0.01) were significantly lower in the complete 
treatment group than in the incomplete treatment group. For 2D CEUS, only the peak-intensity 
values of the tumor from1 month post TACE were significantly different (p<0.01). The correlation 
coefficients between 2D and 3D residual tumor estimates 1–2 weeks post TACE and the estimates 
from MRI were 0.73 and 0.94, respectively, while those from 2D and 3D CEUS 1 month post 
TACE were 0.66 and 0.91, respectively. Quantitative analysis on 2D and 3D CEUS shows 
potential to differentiate patients with complete vs. incomplete response to TACE as early as 1–2 
weeks post treatment.
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1. Introduction
Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer and its 
incidence and mortality rates have been rising for the last decade (Altekruse et al 2014). The 
management of HCC depends on both the stage of the disease and underlying liver function 
(Spârchez et al 2016). Transarterial chemoembolization (TACE) is the preferred treatment 
for patients with intermediate Stage B who do not have symptoms, but have large, multifocal 
tumors without vascular invasion or metastasis beyond the liver, based on the Barcelona 
Clinic Liver Cancer staging system (Sciarra et al 2015). TACE may also be applied to 
patients waiting on liver transplantation as a bridging strategy to limit tumor growth while 
on the waiting list (Sciarra et al 2015).
Conventional TACE (c-TACE) is performed using intra-arterial chemotherapy mixed with 
ethiodol followed by embolization with gelfoam particles or other embolization materials 
(Burrel et al 2012). This method has limitations such as non-uniform arterial obstruction 
from manually prepared gelfoam and toxicity induced by the release of chemotherapy to the 
systemic circulation (Burrel et al 2012). A newer method, TACE with drug-eluting beads 
(DEB-TACE), which slowly release chemotherapy after embolization, has therefore been 
developed (Burrel et al 2012). The efficacy of both TACE techniques depends on complete 
embolization of tumor arterial supply and is determined by residual tumor enhancement on 
imaging post TACE, since histopathologic examination of each nodule is neither feasible nor 
reasonable for patients with HCCs (Spârchez et al 2016, Lammer et al 2009, Shin 2009). 
The objective response (complete or partial response) rate of TACE is about 15–75% of 
tumors (Shin 2009, Marelli et al 2007) and incomplete response to TACE requires repeated 
TACE or alternative treatments (Takayasu et al 2006).
Contrast-enhanced computed tomography (CE-CT) and contrast-enhanced magnetic 
resonance imaging (CE-MRI) are widely used for the assessment of TACE response (Shaw 
et al 2015, Brown et al 2012). The Society of Interventional Radiology guidelines 
recommend delaying follow-up imaging by 4–6 weeks post TACE (Brown et al 2012, 
Kloeckner et al 2010). This time-point for imaging follow-up was suggested due to low 
specificity of both CT and MRI imaging in differentiating peripheral viable tumor from 
peritumoral inflammatory response and also to minimize the amount of imaging artifact 
from intraparenchymal ethiodol on CE-CT (Brown et al 2012, Yan et al 2002). However, 
earlier detection of TACE response could potentially improve the management of HCC 
(Shaw et al 2015, Kono et al 2007).
Contrast-enhanced ultrasound (CEUS) has been evaluated in several studies as an early 
indicator for TACE efficacy (Shaw et al 2015, Kono et al 2007, Cho et al 2015). Recently, 
CEUS for liver imaging was approved by the United States Food and Drug Administration 
and it has been used as a primary imaging modality for many hepatic applications worldwide 
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(Claudon et al 2013). As a modality, CEUS has additional benefits such as availability, 
portability, cost, no nephrotoxicity, and lack of ionizing radiation. The study by Salvaggio et 
al. showed that CEUS performed 1 month post TACE detected all incomplete responses in 
38 HCCs using angiography as reference standard (Salvaggio et al 2010). Cho et al. reported 
that all patients with positive CEUS findings at 4 weeks (8 out of 12 TACE patients) showed 
positivity and residual viable HCC in MRI at 4 or 12 weeks (Cho et al 2015). Kono et al. 
evaluated 23 HCCs within 2 weeks and 10 HCCs within 1 month after c-TACE using CEUS 
(Kono et al 2007). Of these 33 tumors, there were no false-negative results and only one 
false-positive result occurred when the CEUS was performed within 1 day after TACE. 
Similar results were reported in a study with 14 DEB- TACE patients, where CEUS images 
at 1–2 weeks post treatment resulted in 100% accuracy (Shaw et al 2015).
While these studies demonstrated CEUS as an alternative or earlier indicator of TACE 
efficacy, they were limited to qualitative evaluations by CEUS experts using 2D images. The 
accuracy of qualitative evaluation depends largely on the reader’s experience. In the study by 
Shaw et al., the intra- and inter-read variability with CEUS was higher than with CE-MRI or 
CE-CT. They explained that it was caused some readers’ limited experience in CEUS 
relative to other modalities (Shaw et al 2015). Also, evaluating an inherently 3D tumor with 
2D CEUS imaging increases user variability. Moreover, the vasculature of HCCs may be 
heterogeneous over the 2D imaging planes, which can affect the assessment of treatment 
response. Xu et al. used static 3D CEUS to evaluate the treatment response of liver cancer 
(n=107) after local therapies and found that 3D CEUS improved diagnostic confidence 
relative to 2D CEUS (Xu et al 2010). However, the 3D CEUS follow up times ranged from 
10 minutes to 28 months in that study (Xu et al 2010).
A few CEUS studies of TACE have adopted quantitative analyses to better evaluate the 
vasculature within HCCs (Moschouris et al 2010, Uller et al 2011). Moschouris et al. 
calculated the percentage of necrosis within HCCs based on 2D CEUS at 2 days and 35-40 
days post TACE in order to evaluate the amount of early and delayed tumor necrosis by 
DEB-TACE (Moschouris et al 2010). Uller et al. used time-intensity curves from 2D CEUS 
to evaluate the microcirculation of HCCs with intraarterial and intravenous injections of 
contrast agent during DEB-TACE (Uller et al 2011). However, neither the percentage of 
necrosis nor time-intensity curves correlated directly with therapy response. Consequently, 
the purpose of this study was to perform quantitative analysis on 2D and 3D CEUS to 
establish an earlier and accurate indicator for patients requiring retreatment post TACE.
2. Materials and methods
2.1. Subjects
The study was approved by our institutional review board and was compliant with the Health 
Insurance Portability and Accountability Act. All participants in the study provided written 
informed consent. The ultrasound contrast agent utilized in this study was Definity 
(Lantheus Medical Imaging, North Billerica, MA).
Seventeen patients scheduled for TACE for the treatment of HCC participated in the study. 
Participants had to be medically stable and have no known hypersensitivity or allergy to 
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components of Definity. Patients who were pregnant or nursing or having severe cardiac 
complications were excluded. Demographic information was recorded.
2.2. Ultrasound Examinations
Each subject underwent 2D and 3D CEUS exams at three time points: within 2 weeks prior 
to TACE, 1-2 weeks post TACE, and approximately 1 month post TACE. The ultrasound 
exams were performed using a Logiq E9 with C1-6-D (bandwidth of 1-6 MHz with 70° field 
of view) and RAB-2-5-D probes (bandwidth of 1-5 MHz with 85° field of view; GE 
Healthcare, Wauwatosa, WI, USA). All CEUS imaging was performed using the scanner’s 
CEUS mode implemented by the combined technology of amplitude modulation and phase 
inversion. After acquiring baseline images, subjects received a bolus injection of 0.2-0.3 ml 
of Definity intravenously, followed by a 10 ml saline flush for 2D CEUS examination. 2D 
CEUS imaging was performed using a dual-imaging mode, which enabled side by side 
visualization of B-mode and CEUS. Following 2D CEUS examination, subjects waited 10 
minutes for the clearance of the contrast agent before 3D baseline imaging was performed. 
Then, subjects received an identical bolus injection of Definity for a 3D CEUS examination. 
In both of 2D and 3D CEUS, data was collected continuously from the entire tumor and 
surrounding tissue from the arrival of the contrast into the liver until wash-out of the agent 
was observed. Imaging was performed in CEUS mode at low mechanical index below 0.11. 
The frame and volume rate for 2D and 3D CEUS were 8-9 frames/second and 0.3-0.4 
volume/second, respectively. All data were stored for offline analysis.
2.3. Time-intensity curve analysis
For 2D CEUS, a region of interest (ROI) was drawn for both the HCC and the surrounding 
liver tissue on 2D CEUS images. A time-intensity curve was obtained from the area of the 
tumor and the surrounding liver tissues by calculating the mean intensities of the 
corresponding ROI over time. To obtain a time-intensity curve from 3D CEUS, the collected 
3D volume at each time point was analyzed as 8 equidistant 2D slices across the tumor using 
4D View (GE Healthcare, Zipf, Austria). On each 2D CEUS slice, a ROI was drawn for the 
tumor and for the surrounding liver tissue. An example of the ROI selection for 3D CEUS is 
presented in the figure 1. The mean intensities of the volume of tumor and surrounding liver 
tissues were calculated by averaging the intensities within the corresponding ROIs over the 
eight 2D slices using Matlab R2015b (Mathworks, Natick, MA, USA). The same process 
was repeated for all 3D CEUS data at different time points.
2.4. Residual tumor quantification
For the quantification of residual tumor in 2D or 3D CEUS, images or volumes showing the 
peak-intensity were selected based on time-intensity curve analysis described above. The 
residual tumors were quantified using the equation below:
Residual tumor (%) = 100 − Non − enhancing intratumoral volumn or areaTotal tumor volumn or area × 100
For the 3D quantification, the total tumor and non-enhancing intratumoral volumes were 
calculated by adding 15 equidistant 2D areas across the tumor extracted from B-mode 
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volume and CEUS volume, respectively. In 2D, the residual tumor percentage was obtained 
by comparing tumor area on the B-mode image and non-enhanced area on the CEUS image. 
The CEUS volume (i.e. enhanced volume) and non-enhanced area on the CEUS images 
were identified visually.
2.5. Evaluation of TACE response
The TACE response was evaluated based on CE-MRI/CT obtained one month or six months 
post-TACE and assessed by a radiologist blinded to the results from the CEUS exams. 
Complete response was defined as no enhancement shown in 6 month MRI. Incomplete 
response was defined when 1) residual tumor enhancement was seen at MRI 1 month post 
TACE and confirmed on angiography during subsequent retreatment or 2) tumor growth or 
residual enhancement was reported at 6 month follow up. In patients with incomplete 
treatment response, the percentage of residual tumor was quantified in 10% increments 
based on MRI acquired at 1 month post TACE by a radiologist blinded to the ultrasound 
results. The MRI evaluation was performed based on multiple slices over the whole tumor 
volume.
2.6. Statistical analysis
The peak-intensities from the tumor and surrounding liver tissues were grouped by TACE 
response. A Wilcoxon rank sum test was performed to compare complete and incomplete 
responses with a 5% significance level using Matlab. In subjects with incomplete response, 
correlation coefficients (r) were calculated between the residual tumor estimate from MRI 
acquired at 1 month post TACE and the residual tumor estimates from CEUS exams 1-2 
weeks or 1 month post TACE. Also, Bland-Altman plots with repeatability coefficient were 
obtained to assess the agreements.
3. Results
A total of 17 subjects’ data were included in this study (figure 2). Twelve subjects completed 
all 3 exams, while 5 subjects completed 2 exams (one completed exams 1 and 2, two 
completed exams 1 and 3, and two completed exams 2 and 3). Among the 17 subjects, 9 
subjects had complete treatment response and 8 subjects had incomplete treatment response. 
The subjects included 14 males and 3 females. The mean age of the subjects was 64 years 
and the range was 54-78 years. The subjects’ body mass index, tumor size, tumor location, 
and received treatment are summarized in Table 1.
Overall, the HCCs after TACE were observed as hypo-echoic on CEUS 2 weeks and 1 
month post TACE. However, there was one case showing CEUS artifacts and this is 
presented in figure 3. The subject was treated with DEB-TACE and the beads were shown 
hyperechoic on CEUS 2 weeks post treatment. These artifacts disappeared on CEUS 1 
month post TACE.
3.1. Time-intensity curve analysis
The examples of time-intensity curves are shown in figure 4. Prior to TACE, the peak-
intensity values of the tumor on 3D CEUS were similar between the complete and 
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incomplete response groups (90.2 ± 33.4 (mean ± standard deviation) arbitrary unit (AU) vs. 
98.4 ± 46.0 AU; p=0.70) but those from 1-2 weeks (30.0 ± 15.6 AU vs. 66.4 ± 25.4 AU; 
p<0.01) and 1 month post TACE (23.6 ± 13.5 AU vs. 81.8 ± 36.0 AU; p<0.01) were 
significantly lower in the complete response group compared to the incomplete response 
group. These results are summarized in Table 2. The peak-intensity values of the 
surrounding liver tissue region obtained from 3D CEUS did not show differences between 
the complete and incomplete response groups in any case (p>0.12). However, the ratios of 
the tumor peak-intensity to surrounding liver tissue peak-intensity showed the same results 
as the peak-intensity values of tumor regions (Table 2). The ratios of the peak-intensity value 
of tumor to that of surrounding liver tissue regions from 3D CEUS 1-2 weeks and 1 month 
post TACE demonstrated an ability to differentiate complete response from incomplete 
responses (p<0.01 for both cases).
In 2D CEUS, peak-intensity values of the tumor region prior to TACE and 1-2 weeks post 
TACE did not show differences between the complete and incomplete response groups 
(p>0.1; Table 2), while those from the data 1 month post TACE were significantly lower in 
complete response group compared to incomplete response group (p<0.01). Similar to the 
findings from 3D CEUS, peak-intensity values from the surrounding liver tissue did not 
show differences between complete and incomplete response groups (p>0.06; Table 2). The 
ratios of the tumor peak-intensity to surrounding liver tissue peak-intensity showed the same 
results as the peak-intensity values of tumor regions (Table 2). The peak-intensity results 
from 2D and 3D CEUS 2 weeks and 1 month post TACE are compared in figure 5. Overall, 
the peak-intensities from 2D and 3D CEUS were not significantly different (p=0.64).
3.2. Residual tumor quantification
For the subjects with complete response, 2D and 3D CEUS 2 weeks post TACE resulted in 1 
and 2 false positive cases (1 case overlapped), respectively. In case of 2D and 3D 1 month 
post TACE, there were 2 and 3 false-positive cases (1 case overlapped), respectively. Among 
the subjects with incomplete response, there was one subject whose 1 month MRI was 
evaluated as complete response but 6 month follow-up MRI showed a recurrent tumor and 
determined to have incomplete response. For this case, the 2D and 3D CEUS showed 
consistent enhancement within the tumor at both 2 weeks and 1 month post TACE. There 
was no false-negative case in all CEUS evaluations.
The residual tumor estimates from MRI evaluations 1 month post TACE ranged from 0% to 
90% with a mean value of 38% for the subjects with incomplete response. Those from 2D 
and 3D CEUS 1-2 weeks post TACE ranged from 10 to 80% with a mean value of 46% and 
from 20 to 80% with a median value of 37%, respectively. The residual tumor estimates 
from 2D and 3D CEUS 1 month post TACE were 30-80% with a mean value of 51% and 
20-100% with a mean value of 44%, respectively. Figure 6 shows an example of calculating 
tumor size and non-enhanced tumor size using 2D or 3D B-mode and CEUS data acquired 
1-2 weeks post TACE. The case presented in figure 5 had incomplete TACE response and a 
residual tumor estimate from MRI 1 month post TACE of 20%, while the residual tumor 
estimates from 2D and 3D CEUS 1-2 weeks post TACE were 10% and 20%, respectively. 
The correlation coefficients between 2D and 3D residual tumor estimates 1-2 weeks post 
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TACE and the estimates from MRI 1 month post TACE were 0.73 and 0.94, respectively, 
while those from 2D and 3D CEUS 1 month post TACE were 0.66 and 0.91, respectively 
(figure 7). The Bland-Altman plots with repeatability coefficients are presented in figure 8.
4. Discussion
Currently, CE-CT and CE-MRI are widely used for imaging evaluation after TACE and the 
Society of Interventional Radiology guidelines recommend follow-up CE-CT or CE-MRI 
4-6 weeks post TACE (Brown et al 2012, Kloeckner et al 2010). A lack of enhancement 
indicates a lack of residual tumoral blood flow, due to complete embolization and tumor 
necrosis. The 4-6 week time point has been suggested based on experience with the use of 
Lipiodol and CE-CT; the non-tumor bearing liver requires 3-4 weeks to eliminate Lipiodol 
by Kupffer cell phagocytosis (Brown et al 2012). In CE-MRI, the use of low molecular 
weight and water soluble contrast agents renders it difficult to differentiate granulation tissue 
and residual tumor perfusion and to differentiate peripheral viable tumors from 
inflammatory peritumoral infiltration after TACE (Yan et al 2002). Differentiation between 
viable tumor and inflammation can be made in some cases by evaluating enhancement 
washout kinetics. Nevertheless, the cost of imaging and difficulty associated with 
inflammation in many cases has resulted in follow-up imaging recommendation remaining 
at 4-6 weeks (Brown et al 2012). Thus, CEUS has been assessed as an earlier follow-up 
imaging tool for TACE and showed potential to be effective as early as 1-2 weeks (Shaw et 
al 2015, Cho et al 2015). While those studies (Shaw et al 2015, Cho et al 2015) evaluated 
TACE response using a qualitative measure, our results showed that peak-intensity, a 
quantitative measure, could be used to predict TACE response as early as 1-2 weeks. 
Moreover, the residual tumor estimates from 2D CEUS 1-2 weeks were correlated well with 
that from MRI 1 month post TACE (r=0.73) and this correlation improved with the use of 
3D CEUS (r=0.94).
The most common quantitative assessment of therapy response is tumor size change and is 
included in the World Health Organization criteria and Response Evaluation Criteria in Solid 
Tumors (RECIST; Gonzalez-Guindalini et al 2013). However, the bi-dimenstional (Miller et 
al 1981) or uni-dimensional (Therasse et al 2000) measurement of the whole treated tumor 
may not properly reflect therapy response because treatment induced tumor necrosis does 
not cause immediate shrinkage of tumor in parallel (Italian Association for the Study of the 
Liver et al 2013). Thus, the modified RECIST (mRECIST) chose a measurement of viable 
(contrast-enhanced) tumor instead of whole treated tumor though it still recommends the use 
of the longest viable tumor diameter (Lencioni and Llovet 2010). In the study of correlating 
imaging evaluation on CT with pathologic results after TACE, mRECIST underestimated 
and overestimated response in 10.7% and 21.9% of 178 patients, respectively, despite an 
overall acceptable agreement of 67.4% (Bargellini et al 2013).
Previously, the curve fitting and blood flow kinetic modeling was suggested to monitor 
tumor therapy (primarily anti-angiogenic therapies) serially in the same patients focusing on 
partial reduction in vascularity (Doury et al 2017). In this study, the coherent estimation of 
relative parameters was observed from the modeling. While TACE effectiveness is also 
evaluated based on blood flow, the result is binary and determined by complete lack of 
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residual flow. Hence, modeling of this reduction (in which no blood flow is ideally present) 
was not applied in this study.
In this study, the time-intensity curves and residual tumor estimates were obtained from 2D 
as well as 3D CEUS. Interestingly, the peak-intensity of tumor from 3D CEUS differentiated 
the complete response group from the incomplete response group 1-2 weeks and a month 
post TACE, while that from 2D CEUS only did 1 month post TACE. A similar finding was 
demonstrated when correlating residual tumor estimates from 2D and 3D CEUS to those 
from MRI; with 3D estimates showing a better correlation. This could be caused by the 
heterogeneities of TACE response and vascularity within HCCs, which 3D evaluations may 
be better able to reflect (cf. figure 6C). This also could explain why there were more false-
positive cases in 2D CEUS than 3D CEUS in the residual tumor quantification. As expected, 
the peak-intensities of subjects with complete response were much lower than those of 
subjects with incomplete response in this study but they were not completely zero (cf. Table 
2). This could have been caused by the hyperechoic artifacts by drug-eluting beads presented 
in figure 3A. Also the completely treated HCCs were hypoechoic but not anechoic as seen in 
figure 3B. Another cause was the use of circular ROI for all tumors including irregular 
shaped ones. The circular ROI could have contained some of surrounding liver tissue. 
Finally, there were false-positive cases in this study.
Time-intensity curve analysis from CEUS has been used to detect the microvessel density in 
HCCs (Wang et al 2007, Yang et al 2013). In one particular study, there was a significant 
correlation (r=0.89; p<0.05) between peak intensity and microvessel density in the study of 
50 HCC patients (Wang et al 2007). The area under the curve was significantly different 
(p<0.05) between vascular endothelial factor positive and negative groups in a study with 73 
HCC patients (Yang et al 2013). Also, the change in peak value, area under the curve, and 
slope of contrast wash-in between prior to treatment and 15 days post treatment 
differentiated the complete response group from the incomplete response group to the 
treatment of Sorafenib, which blocks tumor angiogenesis in advanced HCCs, in a study with 
28 HCC patients (Zocco et al 2013). These studies (Wang et al 2007, Yang et al 2013, Zocco 
et al 2013) have demonstrated that parameters from time-intensity curve analysis can detect 
changes in vascularity within HCCs and support the results from this study that the effective 
embolization by TACE was reflected in the time intensity curve.
This study had some limitations. In time-intensity curve analysis (2D as well as 3D) the 
same ROIs were maintained throughout the analysis excluding issues arising from subjects’ 
breathing motion. Thus, the time-resolution of time-intensity curve varied among patients. 
Also, the depths of the HCC and the corresponding surrounding liver tissues were not 
always the same, due to difficulties in some scanning windows and the subsequent 
attenuation difference was not accounted for. Only individual parameters were investigated 
at this time, due to the limited data set. In the future, multi-parametric analysis should be 
investigated as these approaches have been shown to improve differentiation in dynamic 
CEUS applications (Postema et al 2015, Wildeboer et al 2017). Finally, while a free-form of 
ROI was used in the residual tumor estimation, a circular-shaped ROI was used for time-
intensity curve analysis, which may generate errors in segmenting tumor from peripheral 
tissue. Future efforts will focus on auto-segmentation algorithms to alleviate this issue.
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5. Conclusions
The peak-intensity of time-intensity curves from 3D CEUS shows the potential to evaluate 
HCC TACE response as early as 1-2 weeks post treatment; albeit based on a limited sample 
size. Also, residual tumor estimates of HCCs from 2D and 3D CEUS 1-2 weeks and 1 
month post TACE matched well with estimates from MRI 1 month post TACE, with 3D 
CEUS showing the best correlation of the two CEUS techniques.
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Figure 1. 
An example of region of interest selections on 8 equidistant 2D slices extracted from 3D 
contrast-enhanced ultrasound imaging is shown. The yellow circle includes surrounding 
liver tissue and the red circle includes the tumor on each 2D slice.
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Figure 2. 
Flowchart of study participants
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Figure 3. 
(A) The contrast-enhanced ultrasound imaging 2 week post transarterial chemotherapy with 
drug-eluting beads showed the hyperechoic artifacts (arrowheads) within the tumor (arrows) 
and (B) these artifacts disappeared on contrast-enhanced ultrasound imaging 1 month post 
treatment.
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Figure 4. 
These examples of time-intensity curves were acquired from a subject with complete 
response prior to TACE (A),1-2 weeks post TACE (B), and approximately 1 month post 
TACE (C) as well as from a subject with incomplete response prior to TACE (D),1-2 weeks 
post TACE (E), and approximately 1 month post TACE (F) using 3D CEUS (A.U: Arbitrary 
Unit). The peak-intensity was obtained directly from each curve.
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Figure 5. 
The peak-intensities from 2D and 3D contrast-enhanced ultrasound 2 weeks and 1 month 
post transarterial chemotherapy were compared between the complete and incomplete 
response groups. (A) The peak-intensities in the tumor and (B) the ratios of the tumor peak-
intensity to surrounding liver tissue peak-intensity showed similar performance to predict 
transarterial chemotherapy response in 3D contrast-enhanced ultrasound. (The central mark 
on each box is the median, the edges of the box are the 25th and 75th percentiles, the 
whiskers extended to approximately ±2.7 standard deviation, and outliers are plotted 
individually).
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Figure 6. 
An example of residual tumor estimation – (A) 2D residual tumor estimate was calculated 
using the difference in tumor area on B-mode and non-enhanced intratumoral area on 
contrast-enhanced ultrasound, each outlined in red dashed line. 3D residual tumor estimate 
was calculated using the differences in tumor and non-enhancing intratumoral volumes, by 
adding 15 equidistant 2D areas across the tumor as outlined in red dashed lines, extracted 
from (B) B-mode volume and (C) contrast-enhanced ultrasound volume, respectively. (D) 
The residual tumor (arrow) was confirmed in magnetic resonance imaging 1 month post 
transarterial chemotherapy.
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Figure 7. 
The residual tumor estimates from 2D and 3D contrast-enhanced ultrasound acquired 1-2 
week and 1 month post transarterial chemotherapy (TACE) were correlated with the residual 
tumor estimate from magnetic resonance imaging 1 month post TACE. The correlation 
coefficients between 2D and 3D residual tumor estimates 1-2 weeks post TACE and the 
estimates from magnetic resonance imaging were 0.73 and 0.94, respectively, while those 
from 2D and 3D contrast-enhanced ultrasound 1 month post TACE were 0.66 and 0.91, 
respectively.
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Figure 8. 
The Bland-Altman plots with repeatability coefficients (RPCs) were obtained between the 
residual tumor estimate from magnetic resonance imaging 1 month post TACE and (A) 2D 
and (B) 3D residual tumor estimates 1-2 weeks post TACE as well as those from (C) 2D and 
(D) 3D contrast-enhanced ultrasound 1 month post TACE (KS: Kolmogorov-Smirnov test, 
SD: Standard deviation).
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